Maximum standardized uptake value in 18F‑fluoro‑2‑deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer

TAKESHI KAJIWARA , YOICHI HIASA , TOMOHIRO NISHINA , TOSHIHIKO MATSUMOTO
Molecular and Clinical Oncology 2 ( 2) 313 -321

8
2014
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].

Junro Kataoka , Toshikazu Moriwaki , Junichirou Nasu , Shinichiro Hori
Gan to kagaku ryoho. Cancer & chemotherapy 34 ( 13) 2249

2007
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].

Toshikazu Moriwaki , Junichirou Nasu , Toshikazu Masumoto , Ken Hirao
Gan to kagaku ryoho. Cancer & chemotherapy 31 ( 9) 1361 -1364

2004
Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer

Toshikazu Moriwaki , Junichirou Nasu , Toshikazu Masumoto , Ken Hirao
Gan to kagaku ryoho. Cancer & chemotherapy 31 ( 9) 1373

1
2004
[A case of Cronkhite-Canada syndrome associated with cholangiocellular carcinoma].

Toshikazu Moriwaki , Masahito Tanimizu , Shoji Hirasaki , Ichinosuke Hyodo
The Japanese journal of gastro-enterology 102 ( 5) 583 -588

5
2005
Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography

Toshikazu Masumoto , Shoji Hirasaki , Ichinosuke Hyodo , Tomohiro Nishina
The Japanese journal of gastro-enterology 101 ( 1) 41 -46

2
2004
[Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].

Masahito Nakauchi , Toshikazu Moriwaki , Junichirou Nasu , Masahito Tanimizu
Gan to kagaku ryoho. Cancer & chemotherapy 30 ( 4) 489

1
2003
[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].

Akinori Asagi , Seijin Nadano , Satoru Takeji , Yoshiou Ikeda
The Japanese journal of gastro-enterology 108 ( 12) 2003 -2009

2011
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].

Nobuyuki Mizunuma , Wasaburo Koizumi , Hideyuki Mishima , Masaki Munakata
Gan to kagaku ryoho. Cancer & chemotherapy 35 ( 2) 255 -260

3
2008
A CASE OF RECTAL CANCER IN CROHN'S DISEASE

Junro Kataoka , Toshikazu Moriwaki , Junichirou Nasu , Masahito Tanimizu
Acta Gastro-enterologica Belgica 50 ( 1) 22 -26

2008
UPPER GASTROINTESTINAL LESIONS IN PATIENTS WITH PANCREATIC CANCER

Toshikazu Moriwaki , Yuusuke Yamauchi , Junichirou Nasu , Masahito Tanimizu
Acta Gastro-enterologica Belgica 47 ( 6) 1220 -1226

2005
Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer

Akinori Asagi , Seijin Nadano , Masahito Tanimizu , Shinichiro Hori
Gan to kagaku ryoho. Cancer & chemotherapy 47 ( 11) 1577 -1581

2020
Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.

Yu Sunakawa , Toshikazu Moriwaki , Takayuki Yoshino , Taito Esaki
Journal of Clinical Oncology 39 120 -120

2021
A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.

Yusuke Amanuma , Tomohiro Nishina , Naoki Takahashi , Takako Eguchi Nakajima
Journal of Clinical Oncology 39 210 -210

2021
Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.

Shuichi Hironaka , Yoshito Komatsu , Shinya Ueda , Kensei Yamaguchi
Japanese Journal of Clinical Oncology 51 ( 6) 879 -885

2021
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

Yoshinori Kagawa , Elena Elez , Jesús García-Foncillas , Hideaki Bando
Clinical Cancer Research 27 ( 9) 2515 -2522

26
2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Fortunato Ciardiello , Maria Di Bartolomeo , Takayuki Yoshino , Taito Esaki
Lancet Oncology 22 ( 6) 779 -789

148
2021